Background: Anemia is one of the most prevalent complications during pregnancy. It is commonly considered a risk factor for poor pregnancy outcomes and can result in complications that threaten the life of both mother...Background: Anemia is one of the most prevalent complications during pregnancy. It is commonly considered a risk factor for poor pregnancy outcomes and can result in complications that threaten the life of both mother and fetus, such as preterm birth, and low birth weight. There is clear evidence to support prompt treatment in all patients with iron deficiency anemia because it is known that treatment improves quality of life and physical condition as well as alleviates fatigue and cognitive deficits. Objective: The aim of the study was to evaluate the value of addition of vitamin B6 to iron in treatment of iron deficiency anemia in pregnant women during the second trimester. Patients and Methods: The study was done by giving anemia pregnant women iron therapy and vitamin B6 which represent group A and iron therapy alone which represents group B. For each pregnant woman, age, parity and gestational history were taken before treatment. All pregnant women took their allocated treatment regularly for three weeks after diagnosis of iron deficiency anemia with complete blood picture and followed up after three weeks. Results: Results of the study revealed that there was no statistically significant difference between the two groups of therapy according to the hemoglobin level before treatment (p-value = 0.734), statistically significant higher mean value in after treatment than before treatment (p-value = 0.048), there was a significant difference in the rate of change of hemoglobin (p-value = 0.011) and body mass index (p-value 0.001). Conclusion: Iron and vitamin B6 seems to increase hemoglobin level more than iron only. Thus, in pregnant women with iron deficiency anemia iron plus vitamin B6 may be considered as a more effective alternative treatment than iron only.展开更多
目的探究血清TSP-1、VEGF及TSP-1/VEGF与早发型重度子痫前期(early onset severe preeclampsia,EOSP)发病的相关性,进一步探究这些指标在妊娠中期预测EOSP的临床价值。方法选取2019年8月~2020年8月在笔者医院收治的妊娠28~33^(+6)周EOS...目的探究血清TSP-1、VEGF及TSP-1/VEGF与早发型重度子痫前期(early onset severe preeclampsia,EOSP)发病的相关性,进一步探究这些指标在妊娠中期预测EOSP的临床价值。方法选取2019年8月~2020年8月在笔者医院收治的妊娠28~33^(+6)周EOSP孕妇38例为病例组,同期门诊正常产检的妊娠28~33^(+6)周健康孕妇40例为对照组,用ELISA法检测两组血清TSP-1、VEGF水平,并进行对比分析,探究血清TSP-1、VEGF及TSP-1/VEGF与EOSP的相关性及诊断价值。回顾性选取2018年9月~2020年8月在笔者医院行中期唐氏筛查(15~20^(+6)周,一般为15~17周)并分娩的孕妇90例为验证组(其中妊娠结局为EOSP孕妇30例,为EOSP组;正常分娩孕妇60例,为非EOSP组),探究TSP-1、VEGF、TSP-1/VEGF对EOSP的预测价值。结果病例组TSP-1值、TSP-1/VEGF值高于对照组(P<0.001),VEGF值低于对照组(P<0.001)。ROC分析TSP-1、VEGF及TSP-1/VEGF的最佳诊断截断值分别为2.44ng/ml、271.21pg/ml、9.13。使用TSP-1、VEGF及TSP-1/VEGF的最佳诊断截断值预测验证组,敏感度分别为70.00%、66.67%、90.00%,特异性为41.67%、90.00%、70.00%,符合率为51.11%、82.22%、76.67%。结论使用TSP-1/VEGF诊断截断值检测EOSP比单独使用VEGF或TSP-1更具有诊断价值。妊娠中期血清TSP-1/VEGF取值9.13对预测EOSP具有一定的价值。展开更多
文摘Background: Anemia is one of the most prevalent complications during pregnancy. It is commonly considered a risk factor for poor pregnancy outcomes and can result in complications that threaten the life of both mother and fetus, such as preterm birth, and low birth weight. There is clear evidence to support prompt treatment in all patients with iron deficiency anemia because it is known that treatment improves quality of life and physical condition as well as alleviates fatigue and cognitive deficits. Objective: The aim of the study was to evaluate the value of addition of vitamin B6 to iron in treatment of iron deficiency anemia in pregnant women during the second trimester. Patients and Methods: The study was done by giving anemia pregnant women iron therapy and vitamin B6 which represent group A and iron therapy alone which represents group B. For each pregnant woman, age, parity and gestational history were taken before treatment. All pregnant women took their allocated treatment regularly for three weeks after diagnosis of iron deficiency anemia with complete blood picture and followed up after three weeks. Results: Results of the study revealed that there was no statistically significant difference between the two groups of therapy according to the hemoglobin level before treatment (p-value = 0.734), statistically significant higher mean value in after treatment than before treatment (p-value = 0.048), there was a significant difference in the rate of change of hemoglobin (p-value = 0.011) and body mass index (p-value 0.001). Conclusion: Iron and vitamin B6 seems to increase hemoglobin level more than iron only. Thus, in pregnant women with iron deficiency anemia iron plus vitamin B6 may be considered as a more effective alternative treatment than iron only.
文摘目的探究血清TSP-1、VEGF及TSP-1/VEGF与早发型重度子痫前期(early onset severe preeclampsia,EOSP)发病的相关性,进一步探究这些指标在妊娠中期预测EOSP的临床价值。方法选取2019年8月~2020年8月在笔者医院收治的妊娠28~33^(+6)周EOSP孕妇38例为病例组,同期门诊正常产检的妊娠28~33^(+6)周健康孕妇40例为对照组,用ELISA法检测两组血清TSP-1、VEGF水平,并进行对比分析,探究血清TSP-1、VEGF及TSP-1/VEGF与EOSP的相关性及诊断价值。回顾性选取2018年9月~2020年8月在笔者医院行中期唐氏筛查(15~20^(+6)周,一般为15~17周)并分娩的孕妇90例为验证组(其中妊娠结局为EOSP孕妇30例,为EOSP组;正常分娩孕妇60例,为非EOSP组),探究TSP-1、VEGF、TSP-1/VEGF对EOSP的预测价值。结果病例组TSP-1值、TSP-1/VEGF值高于对照组(P<0.001),VEGF值低于对照组(P<0.001)。ROC分析TSP-1、VEGF及TSP-1/VEGF的最佳诊断截断值分别为2.44ng/ml、271.21pg/ml、9.13。使用TSP-1、VEGF及TSP-1/VEGF的最佳诊断截断值预测验证组,敏感度分别为70.00%、66.67%、90.00%,特异性为41.67%、90.00%、70.00%,符合率为51.11%、82.22%、76.67%。结论使用TSP-1/VEGF诊断截断值检测EOSP比单独使用VEGF或TSP-1更具有诊断价值。妊娠中期血清TSP-1/VEGF取值9.13对预测EOSP具有一定的价值。
